Hospital
Owensboro Health Twin Lakes Regional Medical Center, INC
Owensboro Health Twin Lakes Regional Medical Center, INC was paid $17.02M by Medicaid between Jan 2021 and Dec 2024, across 261 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoOWENSBORO HEALTH TWIN LAKES REGIONAL MEDICAL CENTER, INC
LEITCHFIELD, KY 42754
LEITCHFIELD, KY 42754
33aNPI1285221416assigned 12/22/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.02M
24GClaims462,644
24DCodes billed261
24AFirst – last monthJan 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#26 of 36
Median peer was paid$36.08M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 75,579 | $2.50M | |
| 2022 | 128,109 | $4.69M | |
| 2023 | 151,422 | $5.62M | |
| 2024incomplete | 107,534 | $4.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 13,776 | 10,980 | $2.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 14,659 | 12,623 | $2.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 3,785 | 2,506 | $972K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 2,731 | 2,130 | $742K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.7% | 8,099 | 7,373 | $633K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,806 | 1,496 | $578K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 2,523 | 1,935 | $564K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.3% | 17,449 | 11,676 | $557K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 4,540 | 4,055 | $542K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 5,624 | 4,395 | $475K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 7,456 | 2,227 | $375K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 7,856 | 4,168 | $335K |
249 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 6,259 | $247K |
| 80050 | General health panel | 1.2% | 8,755 | $204K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 4,712 | $183K |
| 80053 | Comprehensive metabolic panel | 1.0% | 24,397 | $177K |
| G0378 | Hospital observation service, per hour | 1.0% | 1,681 | $174K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.0% | 1,518 | $172K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,848 | $168K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,757 | $160K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,529 | $159K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,477 | $155K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,914 | $145K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,758 | $141K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,656 | $138K |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,986 | $133K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,084 | $131K |
| 87634 | <1% | 1,951 | $121K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,345 | $121K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,692 | $113K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,212 | $106K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 417 | $105K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 395 | $101K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,363 | $88K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 839 | $83K |
| 73630 | <1% | 2,556 | $79K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 295 | $78K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 836 | $76K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 765 | $74K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,275 | $73K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 170 | $69K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 463 | $68K |
| 83880 | <1% | 2,784 | $66K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 693 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,746 | $62K |
| 80081 | <1% | 916 | $61K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,680 | $61K |
| 73610 | <1% | 1,871 | $59K | |
| 71250 | <1% | 291 | $55K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,288 | $53K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 758 | $52K |
| 94760 | <1% | 4,132 | $52K | |
| 80061 | Lipid panel | <1% | 6,042 | $49K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,816 | $49K |
| 87507 | <1% | 206 | $46K | |
| 84484 | <1% | 5,051 | $46K | |
| 73030 | <1% | 1,483 | $43K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 714 | $42K |
| 96376 | <1% | 1,079 | $40K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 158 | $37K |
| 73110 | <1% | 1,427 | $36K | |
| 72100 | <1% | 951 | $33K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,998 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,972 | $32K |
| 83735 | <1% | 6,349 | $32K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 87 | $32K |
| 74018 | <1% | 936 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,766 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,395 | $29K |
| 73130 | <1% | 1,132 | $29K | |
| 82607 | <1% | 2,413 | $28K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 500 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,118 | $27K |
| 73562 | <1% | 977 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,050 | $26K |
| 83690 | <1% | 4,864 | $26K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 32 | $26K |
| 83605 | <1% | 2,967 | $25K | |
| 87040 | <1% | 3,120 | $24K | |
| 81001 | <1% | 9,968 | $23K | |
| J3490 | Unclassified drugs | <1% | 1,969 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,048 | $21K |
| 81025 | <1% | 3,246 | $21K | |
| 86803 | <1% | 1,487 | $19K | |
| 97162 | <1% | 290 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,942 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,037 | $19K |
| 73502 | <1% | 667 | $18K | |
| 86140 | <1% | 4,257 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 85 | $17K |
| 84702 | <1% | 1,267 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,293 | $16K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 322 | $15K |
| 76536 | <1% | 211 | $14K | |
| 85379 | <1% | 1,855 | $14K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 269 | $14K |
| 84439 | <1% | 1,895 | $13K | |
| 82728 | <1% | 1,218 | $13K | |
| 90715 | <1% | 266 | $13K | |
| 99218 | <1% | 346 | $13K | |
| 87186 | <1% | 1,917 | $13K | |
| 82746 | <1% | 1,118 | $13K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,122 | $13K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 742 | $13K |
| 87077 | <1% | 1,962 | $12K | |
| 82550 | <1% | 2,422 | $12K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 828 | $12K |
| 82948 | <1% | 2,218 | $12K | |
| 59025 | Fetal non-stress test | <1% | 154 | $12K |
| 85610 | <1% | 3,827 | $11K | |
| 90686 | <1% | 284 | $10K | |
| 73221 | <1% | 31 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 789 | $10K |
| 73080 | <1% | 348 | $10K | |
| 82803 | <1% | 654 | $10K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 360 | $9K |
| 72131 | <1% | 27 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 360 | $9K |
| 81003 | <1% | 4,444 | $9K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 425 | $9K |
| 85730 | <1% | 1,198 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,941 | $9K |
| 12001 | <1% | 97 | $9K | |
| 71271 | <1% | 82 | $8K | |
| 73560 | <1% | 342 | $8K | |
| 83550 | <1% | 1,148 | $8K | |
| 87070 | <1% | 1,262 | $7K | |
| 70486 | <1% | 27 | $7K | |
| 96367 | <1% | 549 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,731 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $7K |
| 83540 | <1% | 1,276 | $6K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,984 | $6K |
| 97161 | <1% | 531 | $6K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 258 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,719 | $6K |
| 84703 | <1% | 846 | $5K | |
| 85027 | <1% | 909 | $5K | |
| 73140 | <1% | 209 | $5K | |
| 82570 | <1% | 1,026 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 653 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,858 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 519 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 316 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 211 | $4K |
| 86769 | <1% | 201 | $4K | |
| 87807 | <1% | 363 | $4K | |
| 86376 | <1% | 345 | $3K | |
| 82565 | <1% | 331 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 441 | $3K |
| 71101 | <1% | 105 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 20 | $3K |
| 73564 | <1% | 94 | $3K | |
| 93017 | <1% | 27 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 537 | $3K |
| 82248 | <1% | 881 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 348 | $3K |
| 82553 | <1% | 321 | $3K | |
| 82950 | <1% | 629 | $3K | |
| 86703 | <1% | 287 | $3K | |
| 62323 | <1% | 21 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 27 | $3K |
| 82043 | <1% | 621 | $3K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 765 | $3K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 118 | $3K |
| 87081 | <1% | 491 | $3K | |
| 84481 | <1% | 190 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 594 | $2K |
| 72110 | <1% | 77 | $2K | |
| 84550 | <1% | 586 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 456 | $2K |
| 82150 | <1% | 462 | $2K | |
| 87205 | <1% | 627 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 130 | $2K |
| 85652 | <1% | 952 | $2K | |
| 80055 | <1% | 52 | $2K | |
| 84145 | <1% | 146 | $2K | |
| 36600 | <1% | 270 | $2K | |
| 73590 | <1% | 67 | $2K | |
| 84146 | <1% | 133 | $2K | |
| 86003 | <1% | 77 | $2K | |
| 84681 | <1% | 67 | $2K | |
| 00811 | <1% | 14 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 165 | $2K |
| 80320 | <1% | 73 | $2K | |
| 86850 | <1% | 235 | $2K | |
| 81002 | <1% | 645 | $2K | |
| 86039 | <1% | 159 | $1K | |
| 86900 | <1% | 480 | $1K | |
| 84156 | <1% | 456 | $1K | |
| 84112 | <1% | 14 | $1K | |
| 77080 | <1% | 39 | $1K | |
| 84403 | <1% | 64 | $1K | |
| 99406 | <1% | 110 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 114 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 328 | $1K |
| 90656 | <1% | 89 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,254 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $1K |
| 84520 | <1% | 197 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 115 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 347 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 50 | $1K |
| 76770 | <1% | 30 | $1K | |
| 83615 | <1% | 154 | $992.20 | |
| 93971 | <1% | 13 | $967.95 | |
| 86901 | <1% | 408 | $946.18 | |
| 93226 | <1% | 28 | $927.99 | |
| 72050 | <1% | 16 | $786.75 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 44 | $755.58 |
| 82247 | <1% | 210 | $749.08 | |
| 87522 | Neg quan hep c or qual rna | <1% | 17 | $747.59 |
| 72040 | <1% | 14 | $742.58 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 80 | $702.88 |
| 93225 | <1% | 25 | $654.94 | |
| 83516 | <1% | 63 | $652.85 | |
| 76801 | <1% | 14 | $615.86 | |
| 86592 | <1% | 159 | $578.24 | |
| 84436 | <1% | 94 | $570.81 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 32 | $545.03 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $537.38 |
| 73090 | <1% | 34 | $532.00 | |
| 80299 | <1% | 27 | $529.17 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 89 | $519.50 |
| 82270 | <1% | 175 | $516.64 | |
| 87088 | <1% | 97 | $503.91 | |
| 97032 | <1% | 52 | $489.00 | |
| 80076 | <1% | 84 | $467.16 | |
| 80074 | <1% | 12 | $466.46 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 36 | $427.70 |
| 83525 | <1% | 42 | $352.61 | |
| Q3014 | Telehealth originating site facility fee | <1% | 24 | $334.69 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 13 | $296.10 |
| 84153 | <1% | 31 | $284.11 | |
| 86709 | <1% | 28 | $278.12 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 73 | $274.07 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 27 | $256.55 |
| 82784 | <1% | 33 | $239.00 | |
| 86008 | <1% | 13 | $233.09 | |
| 85018 | <1% | 125 | $204.21 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 39 | $189.43 |
| 84100 | <1% | 48 | $184.15 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 61 | $181.34 |
| 84270 | <1% | 15 | $173.84 | |
| 85045 | <1% | 64 | $170.93 | |
| 83001 | <1% | 14 | $164.43 | |
| 85014 | <1% | 94 | $159.83 | |
| 83874 | <1% | 18 | $135.03 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 21 | $95.18 |
| 86706 | <1% | 12 | $95.05 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $84.79 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 29 | $66.22 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $50.98 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 83 | $49.59 |
| 86308 | <1% | 13 | $40.66 | |
| 85651 | <1% | 14 | $26.49 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $19.80 |
| 3044F | 0% | 1,110 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 24 | $0.00 |
| 3046F | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRANALLO, RUSS (VICE PRESIDENT OF FINANCE)
Parent organizationOWENSBORO HEALTH TWIN LAKES REGIONAL MEDICAL CENTER, INC
| Provider | Location | Paid |
|---|---|---|
| Owensboro Health INC | Owensboro, KY | $148.83M |
| Owensboro Health INC | Owensboro, KY | $2.19M |
| Owensboro Health Medical Group INC | Owensboro, KY | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.